SAB Biotherapeutics, Inc. (SABS)
| Market Cap | 258.40M+21.4% |
| Revenue (ttm) | n/a |
| Net Income | -21.79M |
| EPS | -1.29 |
| Shares Out | 90.99M |
| PE Ratio | n/a |
| Forward PE | -2.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,581 |
| Open | 2.91 |
| Previous Close | 2.88 |
| Day's Range | 2.80 - 2.91 |
| 52-Week Range | 2.10 - 5.15 |
| Beta | 0.58 |
| Analysts | none |
| Price Target | 11.64(+309.73%) |
| Earnings Date | Nov 12, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
$SABS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SABS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SABS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SABS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SABS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SABS from public contracts
Source: USAspending.gov
SABS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SABS’s recent data — informational, not investment advice